MSC, an abbreviation for Mesenchymal Stem Cells, refers to adult stem cells present in various tissues, including the umbilical cord, bone marrow, dental pulp, and adipose tissues. These cells possess the remarkable ability to self-replicate and differentiate into specialized cells such as bone, cartilage, muscle, fat, and connective tissues. Their regenerative capabilities manifest through the identification of damaged areas, paracrine signaling, and modulation of immune responses, with MSCs also holding immune privilege status.

In the context of MSC therapy at VIECELL (Malaysia), the stem cells are sourced from the Wharton Jelly of the umbilical cord. This specific type of MSC, akin to those derived from alternative sources, exhibits a unique capacity for self-renewal while maintaining multipotency. Notably, this source carries no ethical concerns compared to other stem cell origins.

Furthermore, the stem cell source adheres to international standard regulations such as cGMP, ISO 9001, and ISO 13485, ensuring compliance and quality in the therapeutic process. The objective of MSC therapy lies in stimulating and expediting cell rejuvenation and regeneration, aiming to decelerate the natural aging process and mitigate chronic diseases, ultimately leveraging the body’s inherent healing and regenerative capacities.